NCT02049190View on ClinicalTrials.gov

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2017

Conditions
Prostate CancerMetastatic Prostate CancerAndrogen-independent Prostate CancerRecurrent Prostate Cancer
Interventions
DRUG

onapristone

DRUG

abiraterone

Trial Locations (1)

SH2 5NG

RECRUITING

Inst of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton Surrey

Sponsors

Lead Sponsor

Arno Therapeutics
All Listed Sponsors
lead

Arno Therapeutics

INDUSTRY

NCT02049190 - Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter